Brain delivery of biologics using a cross‐species reactive transferrin receptor 1 VNAR shuttle

Autor: Stina Syvänen, Greta Hultqvist, Frank S. Walsh, Tobias Gustavsson, J Lynn Rutkowski, Dag Sehlin, Pawel Stocki

Publikováno v: The FASEB Journal. 34:13272-13283

Transferrin receptor 1 (TfR1) mediated transcytosis is an attractive strategy to enhance brain uptake of protein drugs, but translation remains a challenge. Here, a single domain shark antibody VNAR fragment (TXB2) with similar affinity to murine and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::096b68c6da4c11e14820fc68570f777a
https://doi.org/10.1096/fj.202000610rr

Blood‐brain barrier transport using a high affinity, brain‐selective VNAR antibody targeting transferrin receptor 1

Autor: Leandra Northall, Charlotte L M Rasmussen, Laura Thei, Mykhaylo Demydchuk, Aziz Gauhar, Diana Bahu Logan, Frank S. Walsh, Torben Moos, J Lynn Rutkowski, Pawel Stocki, Jaroslaw Szary

Publikováno v: Stocki, P, Szary, J, Rasmussen, C L M, Demydchuk, M, Northall, L, Logan, D B, Gauhar, A, Thei, L, Moos, T, Walsh, F S & Rutkowski, J L 2021, ' Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1 ', F A S E B Journal, vol. 35, no. 2, e21172 . https://doi.org/10.1096/fj.202001787R

Transfer across the blood-brain barrier (BBB) remains a significant hurdle for the development of biopharmaceuticals with therapeutic effects within the central nervous system. We established a functional selection method to identify high affinity si

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0abcb8c69b6a774da4636b59659b1a3a
https://doi.org/10.1096/fj.202001787r

Translational Medicine Lessons from Flurizan's Failure in Alzheimer's Disease (AD) Trial: Implication for Future Drug Discovery and Development for AD

Autor: Giora Z. Feuerstein, Hong I. Wan, J. Steve Jacobsen, J. Lynn Rutkowski

Publikováno v: Clinical and Translational Science. 2:242-247

With current national emphasis on translational research, data exchange systems are needed that bridge basic science and clinical research. To meet this challenge, an electronic system was developed by the Biomedical Informatics Unit (BMIU) of the Un

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af93e51e18e563f24777e9d59272c9ba
https://doi.org/10.1111/j.1752-8062.2009.00121.x

Advances in Neurofibromatosis 2 (NF2): A Workshop Report

Autor: Martin Ruttledge, Michael E. Baser, Richard G. Fehon, Marco Giovannini, E. Antonio Chiocca, Nancy Ratner, J. Lynn Rutkowski, Allan E. Rubenstein, David Beebe, Derald E. Brackmann, Vijaya Ramesh, Frank Lieberman, James F. Gusella, David H. Gutmann, David E. Weinstein, Bruce R. Korf, D. Gareth Evans, Robert L. Martuza, Andrea I. McClatchey, W. Jay Ramsey, Dilys M. Parry, Tyler Jacks, David J. Lim, Bernd G. Seizinger, Stefan M. Pulst, Robert Glazer

Publikováno v: Lim, D J, Rubenstein, A E, Evans, D G, Jacks, T, Seizinger, B G, Baser, M E, Beebe, D, Brackmann, D E, Chiocca, E A, Fehon, R G, Giovannini, M, Glazer, R, Gusella, J F, Gutmann, D H, Korf, B, Lieberman, F, Martuza, R, McClatchey, A I, Parry, D M, Pulst, S M, Ramesh, V, Ramsey, W J, Ratner, N, Rutkowski, J L, Ruttledge, M & Weinstein, D E 2000, ' Advances in neurofibromatosis 2 (NF2) : A workshop report ', Journal of Neurogenetics, vol. 14, no. 2, pp. 63-106 . https://doi.org/10.3109/01677060009083477
Europe PubMed Central

(2000). Advances in Neurofibromatosis 2 (NF2): A Workshop Report. Journal of Neurogenetics: Vol. 14, No. 2, pp. 63-106.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb70d29e01d40262928c4b8493ab3e53
https://doi.org/10.3109/01677060009083477

Molecular studies in 20 submicroscopic neurofibromatosis type 1 gene deletions

Autor: Peter Marynen, Hilde Brems, Conxi Lázaro, Maurizio Clementi, S Mason, Eric Legius, Xavier Estivill, J L Rutkowski, C Lopez Correa

Publikováno v: Human Mutation. 14:387-393

Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder characterized by a marked variability in expression. A more severe phenotype is frequently observed in the group of patients carrying a large NF1 deletion. To study the extent of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1655ac363ef4400226a49c78df85a636
https://doi.org/10.1002/(sici)1098-1004(199911)14:5<387::aid-humu4>3.0.co